Delivery Order SPE2DR25D2216-SPE2DR26F7UR3
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen injectors, with an ultimate completion date of September 12, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's larger prime contract vehicle with DLA. The pharmaceutical products will be delivered to AmerisourceBergen's corporate headquarters location in...
- The Defense Logistics Agency awarded a delivery order valued at $4,939.58 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen injectors on December 16, 2025, with an ultimate completion date of January 8, 2026. This firm fixed-price contract represents a non-competitive set-aside delivery against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Tezspire 210 mg/1.91 ml pen injectors, valued at $2,343.59, with an ultimate completion date of September 16, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal medical procurement needs. The contract is performed from the company's corporate...
- The Defense Logistics Agency has awarded a delivery order valued at $4,939.58 to AmerisourceBergen Drug Corp for the supply of Tezspire 210 mg/1.91 mL pen injectors. This is a firm fixed price, competitively awarded contract with an ultimate completion date of November 28, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child delivery order under a larger contract vehicle, this award leverages AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $9,879.12 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen injectors, with an ultimate completion date of December 12, 2025. This is a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen injectors, valued at $2,343.59, with an ultimate completion date of September 9, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued competitively under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a $999,999,999.00 potential value through December 2026. The place...
- The Defense Logistics Agency awarded a $4,939.58 firm fixed-price delivery order to AmerisourceBergen Drug Corp on November 28, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors. The contract, which carries no set-aside designation, represents a competitively awarded transaction under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. Performance will be completed by December 19, 2025, at...
- The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, with an ultimate completion date of August 8, 2025. This is a firm fixed-price contract with no set-aside designation, performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract represents a competitive award to the pharmaceutical distributor, which serves as a critical vendor...
- The Defense Logistics Agency awarded a $14,818.68 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen injectables on November 12, 2025, with completion targeted for December 4, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was competitively awarded with no set-aside designation and reflects...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 5, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors, valued at $2,469.78 with a completion date of December 29, 2025. This firm fixed price delivery order was competitively awarded without set-aside provisions and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December...
- SPE2DR25D2216Indefinite Delivery Contract
- SPE2DR25D2216-SPE2DR26F7UR3Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,469.78 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen injectors, with an ultimate completion date of January 13, 2026. This is a firm fixed price, non-set-aside contract with performance at the vendor's Conshohocken, Pennsylvania location. The award represents a single delivery order under a larger indefinite delivery contract vehicle. This delivery order falls under AmerisourceBergen Drug Corp's $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which extends through December 2026 and serves as the primary pharmaceutical support mechanism for military healthcare programs globally. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp supplies a comprehensive range of medications and medical supplies to support Defense Health Agency operations and other federal healthcare systems. Tezspire is a specialty pharmaceutical product used in respiratory treatment, consistent with the company's portfolio of brand-name and specialized medications delivered through the DLA Medical Supply Chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.5k | 12/18/25 |